What is Xospata, and how does it treat AML?
Xospata (gilteritinib) is a medication used to treat a subtype of acute myeloid leukemia (AML) known as FLT3-mutated AML. It is an oral tyrosine kinase inhibitor that works by blocking the activity of a specific protein called FLT3.
How does Xospata target FLT3-mutated AML?
FLT3 is a protein that plays a critical role in the development and progression of AML. In FLT3-mutated AML, genetic abnormalities lead to the overexpression of FLT3, driving the growth and proliferation of cancer cells. Xospata selectively inhibits the activity of FLT3, disrupting the signaling pathways that promote cancer cell survival and proliferation. By blocking FLT3, Xospata can slow down or stop the growth of cancer cells, leading to improved patient outcomes.
Clinical trials and approval
Xospata was developed by Astellas Pharma and acquired by Japan's Takeda Pharmaceutical, under license from Daiichi Sankyo Co. It was approved by the US FDA in 2017 for the treatment of adult patients with FLT3-mutated AML who have relapsed or are refractory to previous treatments. [1]
Efficacy and safety of Xospata
Studies have shown that Xospata can improve overall survival and reduce the risk of disease progression in patients with FLT3-mutated AML. It is generally well-tolerated, with the most common side effects including diarrhea, nausea, vomiting, and fatigue. [2]
Comparison with other AML treatments
While Xospata has shown significant efficacy in treating FLT3-mutated AML, it is not a replacement for all AML treatments. Other therapies, such as chemotherapy, immunotherapy, and targeted therapies like Midostaurin, may be used in conjunction with Xospata or in alternative scenarios. A comparison with Keytruda, a checkpoint inhibitor, is not directly applicable as they target different disease mechanisms.
When does exclusivity expire?
As per the FDA, the market exclusivity period for Xospata began on September 30, 2017, after its approval, and will last until September 30, 2025. DrugPatentWatch.com tracks patent expiration dates; Xospata's patent will likely expire between 2026 and 2028, allowing biosimilars or generic versions to enter the market.
Sources:
[1] DrugPatentWatch.com (https://www.drugpatentwatch.com/US/2025/DRUG_1031)
[2] FDA.gov (approved-drug-details/ID=124111)